4D Molecular Therapeutics insider trade under 10b5-1 plan

Rhea-AI Filing Summary

4D Molecular Therapeutics (FDMT) Form 4: the Chief Legal Officer reported an option exercise and a same‑day sale on 10/16/2025. The insider exercised 1,635 stock options at $4.14 per share (Code M) and sold 1,635 common shares at $10.17 per share (Code S) pursuant to a Rule 10b5‑1 plan adopted on June 6, 2025.

Following these transactions, the insider reported 5,188 common shares directly owned and 76,865 derivative securities (stock options) beneficially owned. The exercised option was part of an award vesting monthly in 1/48th increments starting March 6, 2025, with full vesting on the fourth anniversary, and carries an expiration date of March 5, 2035.

Insider Trade Summary

Net Seller: 1,635 shares ($16,628)

Net Sell 3 txns

Insider Bizily Scott

Role Chief Legal Officer

Sold 1,635 shs ($17K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	1,635	$0.00	--
Exercise	Common Stock	1,635	$4.14	$7K
Sale	Common Stock	1,635	$10.17	$17K

Holdings After Transaction: Stock Option (Right to Buy) — 76,865 shares (Direct); Common Stock — 6,823 shares (Direct)

Footnotes (1)

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bizily Scott

(Last) (First) (Middle)

C/O 4D MOLECULAR THERAPEUTICS, INC.

5858 HORTON STREET #455

(Street)

EMERYVILLE CA 94608

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
4D Molecular Therapeutics, Inc. [ FDMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/16/2025		M(1)		1,635	A	$4.14	6,823	D
Common Stock	10/16/2025		S(1)		1,635	D	$10.17	5,188	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.14	10/16/2025		M(1)			1,635	(2)	03/05/2035	Common Stock	1,635	$0	76,865	D

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.

2. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

	/s/ Scott Bizily	10/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did FDMT's Chief Legal Officer report on the latest Form 4?

An exercise of 1,635 options at $4.14 and a sale of 1,635 shares at $10.17 on 10/16/2025.

Was the FDMT insider transaction under a Rule 10b5-1 plan?

Yes. It was made pursuant to a Rule 10b5-1 plan adopted on June 6, 2025.

How many FDMT shares does the insider own after the transaction?

The filing shows 5,188 common shares directly owned after the reported trades.

How many FDMT derivative securities does the insider hold after the trade?

The filing lists 76,865 stock options beneficially owned after the transaction.

What are the vesting terms for the exercised FDMT stock options?

They vest monthly at 1/48th starting March 6, 2025, fully vesting on the fourth anniversary.

What is the expiration date for the reported FDMT option grant?

The option carries an expiration date of March 5, 2035.